{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:18:58Z","timestamp":1788884338017,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.semarthrit.2025.152712","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:33:49Z","timestamp":1741880029000},"page":"152712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7828-0714","authenticated-orcid":false,"given":"Shuhui","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-5768","authenticated-orcid":false,"given":"Shuang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0001","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152712_bib0002","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.autrev.2017.01.008","article-title":"Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: results from a multicenter, international and retrospective study","volume":"16","author":"Bartoloni","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"32","key":"10.1016\/j.semarthrit.2025.152712_bib0003","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0004","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1136\/annrheumdis-2012-201800","article-title":"Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients","volume":"73","author":"Aggarwal","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152712_bib0005","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152712_bib0006","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152712_bib0007","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jamaneurol.2017.0934","article-title":"Skeletal muscle involvement in antisynthetase syndrome","volume":"74","author":"Noguchi","year":"2017","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152712_bib0008","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1007\/s13311-018-00676-2","article-title":"Autoimmune myopathies: updates on evaluation and treatment","volume":"15","author":"McGrath","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0009","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13075-023-03116-5","article-title":"Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome","volume":"25","author":"Arcani","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152712_bib0010","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/s41423-019-0331-0","article-title":"Serum-circulating his-tRNA synthetase inhibits organ-targeted immune responses","volume":"18","author":"Adams","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152712_bib0011","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152712_bib0012","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term Rituximab use to maintain remission of antineutrophil cytoplasmic antibody\u2013Associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0013","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10067-021-05871-9","article-title":"Rituximab as a glucocorticoid-sparing agent in idiopathic inflammatory myopathies: a retrospective single-center cohort study","volume":"41","author":"Egeli","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152712_bib0014","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/art.37754","article-title":"Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial","volume":"65","author":"Oddis","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152712_bib0015","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in Rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis: clinical and serologic Predictors of improvement in myositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152712_bib0016","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1093\/rheumatology\/key450","article-title":"Efficacy and safety of rituximab in anti-synthetase antibody positive and negative subjects with idiopathic inflammatory myopathy: a registry-based study","volume":"58","author":"Leclair","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152712_bib0017","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome\u2014A retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152712_bib0018","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1097\/MJT.0000000000000245","article-title":"Successful treatment of life-threatening interstitial lung disease secondary to antisynthetase syndrome using rituximab: a case report and review of the literature","volume":"23","author":"Dasa","year":"2016","journal-title":"Am J Ther"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152712_bib0019","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.drudis.2016.06.009","article-title":"Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?","volume":"21","author":"Reddy","year":"2016","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152712_bib0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/annrheumdis-2021-221756","article-title":"Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series","volume":"81","author":"Kvacskay","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"10.1016\/j.semarthrit.2025.152712_bib0021","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"JAMA"},{"issue":"10379","key":"10.1016\/j.semarthrit.2025.152712_bib0022","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0023","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152712_bib0024","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores: prevalent new-user designs","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152712_bib0025","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1002\/pds.5656","article-title":"Prevalent new user designs: a literature review of current implementation practice","volume":"32","author":"Tazare","year":"2023","journal-title":"Pharmacoepidemiology and Drug"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152712_bib0026","doi-asserted-by":"crossref","first-page":"309","DOI":"10.55563\/clinexprheumatol\/8xj0b9","article-title":"Defining anti-synthetase syndrome: a systematic literature review","volume":"40","author":"Zanframundo","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0027","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC International Workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14\u201316 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0028","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000725","article-title":"Major infections in newly diagnosed systemic lupus erythematosus: an inception cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0029","article-title":"Matching methods for causal inference: a review and a look forward","volume":"25","author":"Stuart","year":"2010","journal-title":"Statist Sci [Internet]"},{"issue":"469","key":"10.1016\/j.semarthrit.2025.152712_bib0030","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1198\/016214504000001880","article-title":"Causal inference using potential outcomes: design, modeling, decisions","volume":"100","author":"Rubin","year":"2005","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152712_bib0031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.semarthrit.2025.152712_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152560","article-title":"Efficacy and safety of a step-down regimen of low dosage of glucocorticoids combined with early administration of synthetic or biologic immunosuppressants in anti-synthetase syndrome: a pilot study","volume":"69","author":"Conticini","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152712_bib0033","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"Aggarwal","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152712_bib0034","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European scleroderma trial and research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152712_bib0035","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00614-2023","article-title":"Combining rituximab with mycophenolate for the treatment of interstitial lung disease","volume":"61","author":"Volkmann","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152712_bib0036","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2665-9913(21)00059-X","article-title":"COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study","volume":"3","author":"Avouac","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152712_bib0037","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s15010-019-01271-z","article-title":"HBsAg-negative\/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation?","volume":"47","author":"Dr\u00f6\u00dfler","year":"2019","journal-title":"Infection"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152712_bib0038","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3899\/jrheum.161480","article-title":"Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies","volume":"44","author":"Shi","year":"2017","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152712_bib0039","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti Ro\/SSA antibodies causes a more severe interstitial l","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152712_bib0040","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody\u2013associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152712_bib0041","article-title":"Description and analysis of a novel subtype of the Anti-synthetase syndrome characterized by frequent attacks of fever and systemic inflammation in a single-center cohort study","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152712_bib42","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","article-title":"Rituximab treatment in patients with refractory inflammatory myopathies","volume":"50","author":"Mahler","year":"2011","journal-title":"Rheumatology (Oxford)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000836?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225000836?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T01:50:21Z","timestamp":1767750621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225000836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":42,"alternative-id":["S0049017225000836"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152712","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of anti-CD20 monoclonal antibodies versus csDMARDs in anti-Jo-1 antisynthetase syndrome: A retrospective cohort study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152712"}}